TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01925521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part1 : OPS-2071
Description: single oral dose under fasted condition

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part1 : Placebo of OPS-2071
Description: single oral dose under fasted condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part2 : OPS-2071
Description: multiple twice-daily oral dosing for 5-7days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part2 : Placebo of OPS-2071
Description: multiple twice-daily oral dosing for 5-7days
Study: NCT02912871

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRIgHIFU unilateral subthalamotomy
Description: High Intensity focused ultrasound unilateral subthalamotomy: Unilateral thermolesion in the Subthalamic nucleus performed by High Intensity Focused ultrasound
Study: NCT01586091

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levocetirizine Oral Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fexofenadine 60 Mg Oral Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Study: NCT03319550

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Casein
Description: see experimental description

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey
Description: see experimental description

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine-enriched whey
Description: see experimental description
Study: NCT01748760

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CLASP-A intervention
Description: Three individual sessions with adolescent patient using acceptance based strategies and motivational interviewing techniques. Sessions focused on identifying personalized risk factors for suicidal behavior, identifying values and goals, and development of personalized safety plan.
Study: NCT04537897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 474121
Description: BI474121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 474121
Description: BI474121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 474121
Description: BI474121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 474121
Description: BI474121

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BI 474121
Description: BI474121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam
Study: NCT01748760

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Referral to outpatient treatment as part of routine discharge planning.
Study: NCT02085655

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegaspargase
Description: pegaspargase: 2000U/m2 im on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: pegaspargase: 2000U/m2 im on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2, ivd on day 1 and 8 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT04537897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Midazolam

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04463784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz 400Mg Oral Tablet
Description: The experimental arm will receive 400mg efavirenz per randomization with other two antiretroviral medication (tenofovir and lamivudine).
Study: NCT02085655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 100mg/m2 ivd on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: 3000m g/m2 civ 6-hour on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 40mg ivd on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 100-200mg, PO, after chemotherapy
Study: NCT01769521

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensimed Triggerfish®
Description: Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
Study: NCT02522377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: inter venous injections

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: inter venous injections
Study: NCT02503891

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MP-1 Polymer on Ceramic Articulation system
Description: MP-1 Polymer liner on Ceramic head
Study: NCT04292938

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low carbohydrate ketogenic diet
Description: Dietary modification, including the use of supplements, with the aim of reaching a lipid/carbohydrate-protein 3:1 ratio with a minimum 1g/Kg/die in protein
Study: NCT03770143

Intervention type: OTHER
Intervention: Feeding with palm olein formula
Study: NCT03977077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin binding taxol
Description: 125mg/m2, d1, 8, intravenous infusion for 30min, 1 cycle every 3 weeks;Other combined chemotherapy drugs and drug doses shall be administered by clinicians according to the guidelines and the actual situation of clinical patients.
Study: NCT04463784

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz 600Mg Oral Tablet
Description: The active comparator arm will receive 600mg efavirenz per randomization with other two antiretroviral medication (tenofovir and lamivudine).
Study: NCT05177523

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Each enrolled subject will undergo a MRI at baseline and a second MRI at 2 years (+/- 3 months) follow-up.

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Each enrolled subject will undergo a MRI at baseline and a second MRI at 2 years (+/- 3 months) follow-up.
Study: NCT00583739

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: Gentle Yoga for breast cancer survivors, 1 time weekly, for 8 weeks.
Study: NCT05177523

Intervention type: OTHER
Intervention: Neurocognitive examination for healthy subjects
Description: Neurocognitive examination for healthy subjects will be performed at both baseline and follow-up

Intervention type: OTHER
Intervention: blood sampling
Description: Each enrolled subject will undergo a blood sampling (10 ml) at baseline
Study: NCT01163435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose dual therapy
Description: rabeprazole 20 mg qid,amoxicillin 750 mg qid for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sequential therapy
Description: rabeprazole 20 mg, amoxicillin 1000 mg, bid for 5 days, then rabeprazole 20 mg , metronidazole 500 mg, clarithromycin 500 mg, bid for next 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clarithromycin-based triple therapy
Description: rabeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg, bid for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levofloxacin-based triple therapy
Description: rabeprazole 20 mg, amoxicillin 1000 mg, levofloxacin 250 mg, bid for 7 days
Study: NCT03469843

Intervention type: OTHER
Intervention: Non intervention
Description: patients without intervention
Study: NCT00684697

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: iron
Description: High, intermediate and low iron dosage orally for 2 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: iron
Description: High, intermediate and low iron dosage orally for 2 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: iron
Description: High, intermediate and low iron dosage orally for 2 months
Study: NCT00926887

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erchonia(R) EML Laser
Description: Low level laser red light of 635 nm and delivering 1.5 joules/cm2.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo Laser
Description: Inactive light
Study: NCT03221543

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReeVue Indirect Calorimeter
Description: The ReeVue Indirect Calorimeter will be used in this study to measure the resting metabolic rate. The test takes approximately ten minutes to complete. The subject should prepare for the test by avoiding stimulants and exercise on the day of the test, as well as eating meals four hours before the test. The subject will be seated during the test. They will be given a nose clip that looks like a clothes pin to be placed on their nose. A plastic mouth piece that allows all of the air they breathe to come in through the top of the mouth piece and the air they breathe out to go into the ReeVue Calorimeter will also be provided. The subject will remain in this position for ten minutes until the testing is complete.
Study: NCT02300103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Tablet (s) administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study: NCT04277403

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hippocampal Avoiding Whole Brain Radiation Therapy with Simultaneous Integrated Boost
Description: Hippocampal avoiding Whole brain radiation therapy (HA-WBRT) with volumetric modulated arc therapy (VMAT) with a prescribed dose of 30Gy in 12 fractions, 2.5Gy per fraction and a simultaneously integrated boost (SIB) to each brain metastasis of 51Gy to 95% of PTV in 12 Fractions, 4.25Gy per fraction.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Single session or hypofractionated stereotactic radiosurgery
Description: Single session or hypofractionated stereotactic radiosurgery (SRS) of multiple brain metastases. Single session SRS will be delivered in 18 to 22Gy to the tumour encompassing 80% Isodose. Hypofractionated stereotactic radiosurgery (HfSRS) will be delivered in 5 sessions of 6Gy each to the tumour encompassing 80% isodose.
Study: NCT01192698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV interferon
Description: IV interferon 5MU during anhepatic phase
Study: NCT01647685

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nanocort
Description: Two weekly IV infusions of 150 mg Nanocort (PEG-liposomal prednisolone sodium phosphate).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Two weekly infusion iv methylprednisolone sodium succinate 125 mg infusion.
Study: NCT05177523

Intervention type: OTHER
Intervention: blood sampling
Description: Each enrolled subject will undergo a blood sampling (10 ml) at baseline
Study: NCT01647685

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution (same solution brand as used to dilute/prepare Nanocort injection)
Study: NCT02736812

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: French Lyophilized Plasma
Description: During the pre-hospital phase, the main events related to this arm are~* Blood samples taken before treatment (TP, fibrinogen, platelets, RBC, grouping)~* Usual pre-hospital care according to recommendations in best practices~* Administration of FLYP

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Normale Saline Solution
Description: During the pre-hospital phase, the main events related to this arm are~* Blood samples taken before treatment (TP, fibrinogen, platelets, RBC, grouping)~* Usual pre-hospital care according to recommendations in best practices~* Administration of Normale Saline Solution
Study: NCT00907088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy milk intake
Description: In addition to the standard nutrition counselling, the intervention group will receive specific information regarding healthy milk intake (2 cups per day, maximum 16 ounces) and the potential negative health effects of prolonged bottle use and excessive milk intake including anemia, iron depletion, and dental carries.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard nutrition counselling
Description: Parents of children will receive nutrition counselling via trained study personnel, including recommendations for iron containing food choices and timing of cow's milk introduction. This group will also receive a colourful nutrition book.
Study: NCT03107000

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabeculectomy
Description: Incisional surgery for glaucoma

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phako-trabeculectomy
Description: Incisional surgery for glaucoma plus cataract
Study: NCT02882984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid Other Name: Gefitinib/Tarceva/Icotinib
Description: radiation given along with one of kind TKI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid Other Name: Gefitinib/Tarceva/Icotinib
Description: radiation given along with one of kind TKI

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: WBRT
Description: 3750 cGy in 15 fractions given within 3 weeks time.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HFSRS
Description: All HFSRS given in 5 fractions. dose per fraction ranges from 5 to 8 Gy depending on the target volume and organs at risk tolerance.
Study: NCT04411407

Intervention type: DEVICE
Group type: OTHER
Intervention: PROM registration via the DANBIO WebApp and the outpatient touchscreen in a randomised order
Description: PROM registration via the DANBIO WebApp and the outpatient touchscreen in a randomised order

Intervention type: DEVICE
Group type: OTHER
Intervention: PROM registration via the DANBIO WebApp and the outpatient touchscreen in a randomised order
Description: PROM registration via the DANBIO WebApp and the outpatient touchscreen in a randomised order
Study: NCT00328809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spironolactone
Description: spironolactone administered to ESRD patients at low dose
Study: NCT03694652

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACE
Description: Patient-centered Assessment and Counseling for Exercise \[PACE\] program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PACE
Description: Patient-centered Assessment and Counseling for Exercise \[PACE\] program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Motivating healthy dietary habits

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Motivating healthy dietary habits

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: App
Description: Using an app to deliver communication to the participant.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face
Description: Using in person meetings and/or phone communication with the participant.
Study: NCT04545372

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Study: NCT03298100

Intervention type: OTHER
Intervention: Scoring model
Description: Determining risk factors an calculating the risk score, recurrent vaginal bleeding 3, hypertension 2, age and endometrial thickness 1 for each
Study: NCT04465149

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Third Molar Germectomy
Description: Surgical extraction of Third Molars that exhibits at least a third of its root in formation, with a periodontal ligament discernible on panoramic x-ray (defined as germectomy).
Study: NCT06742242

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lymphaticovenous anastomosis
Description: supermicrosurgical lymphatic vessel to recipient ven lumen-to-lumen coaptation
Study: NCT02622022

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine hydrochloride
Study: NCT03599752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Receive chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Receive chemotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metastasectomy
Description: Undergo pulmonary metastasectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metastasectomy
Description: Undergo pulmonary metastasectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metastasectomy
Description: Undergo pulmonary metastasectomy
Study: NCT01950351

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03151798

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phase II: Lifestyle treatment
Description: Subjects will undergo energy restriction and exercise training over a 9 month period.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Phase II: Control treatment
Description: Subjects will receive dietary advice and receive information on a stretching program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phase I: Observational studies
Description: The liver samples from patients undergoing bariatric surgery or a diagnostic liver biopsy will undergo in vitro assays to determine the capacity of the tissue to burn fat
Study: NCT04594252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1840
Description: Administered orally as tablets.
Study: NCT04527315

Intervention type: OTHER
Intervention: Questionnaires
Description: Various questionnaires will be used to assess short and long-term impacts of depression, anxiety, and other indicators of overall mental health and quality of life

Intervention type: OTHER
Intervention: Questionnaires
Description: Various questionnaires will be used to assess short and long-term impacts of depression, anxiety, and other indicators of overall mental health and quality of life
Study: NCT04054310

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Liver Multi Scan
Description: MRI to create cT1, T2\* and PDFF images of patients liver.
Study: NCT02234622

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Holistic Yoga Program
Description: The Holistic Yoga Program (HYP) (postures, breathing practices, deep muscle contraction practices, relaxation) is a 16 week, 90 minute weekly group intervention.
Study: NCT03646292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: The investigators will compare the degree of liver fat before and after pioglitazone monotherapy.
Study: NCT03017989

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRF imaging
Description: By using a fluorescence imaging device (with an adapted light source and camera), a fluorescent dye can be made visible. By injecting the fluorescent dye intravenously, the vascularization will be visible. Thereby, structures with altered vascularization are expected to 'light up' differently than the surrounding.
Study: NCT02234622

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness Lifestyle Program
Description: The Wellness Lifestyle Program (WLP) is a 16 week, 90 minute weekly group intervention consisting of low intensity walking with didactics about wellness topics.
Study: NCT01870492

Intervention type: DRUG
Intervention: Activase
Description: Patients treated with Activase
Study: NCT00857376

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha lipoic acid at 3 doses compared to placebo
Description: This is a randomized study comparing the antioxidant effects of 3 doses of alpha lipoic acid (total of 600 mg daily, 1200 mg daily and 1800 mg daily) compared to placebo. These doses will be taken as 2 pills 3 times a day for 8 to 10 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha lipoic acid at 3 doses compared to placebo
Description: This is a randomized study comparing the antioxidant effects of 3 doses of alpha lipoic acid (total of 600 mg daily, 1200 mg daily and 1800 mg daily) compared to placebo. These doses will be taken as 2 pills 3 times a day for 8 to 10 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha lipoic acid at 3 doses compared to placebo
Description: This is a randomized study comparing the antioxidant effects of 3 doses of alpha lipoic acid (total of 600 mg daily, 1200 mg daily and 1800 mg daily) compared to placebo. These doses will be taken as 2 pills 3 times a day for 8 to 10 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Alpha lipoic acid at 3 doses compared to placebo
Description: This is a randomized study comparing the antioxidant effects of 3 doses of alpha lipoic acid (total of 600 mg daily, 1200 mg daily and 1800 mg daily) compared to placebo. These doses will be taken as 2 pills 3 times a day for 8 to 10 weeks.
Study: NCT02810691

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soluble fiber supplementation
Description: Two different doses of psyllium powder will be diluted in 250 ml of orange-flavored water and drink in 5 minutes before breakfast.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soluble fiber supplementation
Description: Two different doses of psyllium powder will be diluted in 250 ml of orange-flavored water and drink in 5 minutes before breakfast.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for fiber supplementation)
Description: Placebo will consist of 250 ml of orange-flavored water to be drink in 5 minutes before breakfast.
Study: NCT02183428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 1356
Study: NCT01870492

Intervention type: DEVICE
Intervention: Endovascular therapy
Description: Patients treated with endovascular therapy, such as IA-tPA, mechanical thrombectomy, etc for acute ischemic stroke or transient ischemic attack.
Study: NCT02183428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide